<div id="readability-page-1">09:26 AM EST, 01/05/2026 (MT Newswires) -- Health care stocks were lower premarket Monday, with the iShares Biotechnology ETF (IBB) slipping 0.3% and the State Street Health Care Select Sector SPDR ETF ( XLV ) down 0.5%.GH Research ( GHRS ) shares were up more than 38% after the company said the US Food and Drug Administration has lifted the clinical hold on its investigational new drug application for GH001 as a potential treatment for depression, allowing the company to proceed with subject enrollment in the US.Novo Nordisk ( NVO ) stock was up more than 2% after the company said it will offer its 1.5 mg and 4 mg oral weight loss drug Wegovy at $149 per month to self-paying patients in the US, starting Jan. 5.Gyre Therapeutics ( GYRE ) shares were nearly 6% higher after the company said its Chinese unit reached an agreement with China's Center for Drug Evaluation to seek conditional approval for its liver fibrosis treatment Hydronidone. MT Newswires does not provide investment advice. Unauthorized reproduction is strictly prohibited.</div>

GYRE

GHRS

諾和諾德公司

週一盤前，醫療保健類股票下跌，iShares 生物技術 ETF 下跌 0.3%，State Street 醫療保健精選行業 SPDR ETF 下跌 0.5%。GH Research 的股票在 FDA 解除其 GH001 藥物申請的臨牀限制後飆升超過 38%。諾和諾德公司的股票上漲超過 2%，因其宣佈 Wegovy 減肥藥的月售價為 149 美元。Gyre Therapeutics 的股票在與中國達成肝纖維化治療的有條件批准協議後上漲近 6%

板塊更新：醫療保健類股在週一盤前下跌